Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study

Yan Gao, Frederick A Masoudi, Shuang Hu, Jing Li, Haibo Zhang, Xi Li, Nihar R Desai, Harlan M Krumholz, Lixin Jiang, China PEACE Collaborative Group

Abstract

Background: Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources. However, the rates and recent trends of aspirin use for the early treatment of AMI in China are unknown.

Methods and results: Using data from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), we identified a cohort of 14 041 patients with AMI eligible for early aspirin therapy. Early use of aspirin for AMI increased over time (78.4% in 2001, 86.5% in 2006, and 90.0% in 2011). However, about 15% of hospitals had a rate of use of <80% in 2011. Treatment was less likely in patients who were older, presented with cardiogenic shock at admission, presented without chest discomfort, had a final diagnosis of non-ST-segment elevation acute myocardial infarction, or did not receive reperfusion therapy. Hospitalization in rural regions was also associated with aspirin underuse.

Conclusions: Despite improvements in early use of aspirin for AMI in China, there remains marked variation in practice and opportunities for improvement that are concentrated in some hospitals and patient groups.

Clinical trial registration url: ClinicalTrials.gov Unique identifier: NCT01624883.

Keywords: acute myocardial infarction; aspirin; quality of care.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Figures

Figure 1.
Figure 1.
Flow diagram of the study sample. AMI indicates acute myocardial infarction.
Figure 2.
Figure 2.
Trends in early aspirin use for acute myocardial infarction in 2001, 2006, and 2011 by Chinese Geographic Regions. P<0.001 for trend for all 5 regions. CR indicates Central‐rural; C/WU, Central/Western‐urban; ER, Eastern‐rural; EU, Eastern‐urban; WR, Western‐rural.
Figure 3.
Figure 3.
Trends of early aspirin therapy in rural and urban regions in 2001, 2006, and 2011 (hospitals with sample size

Figure 4.

Factors associated with early use…

Figure 4.

Factors associated with early use of aspirin in multivariable model (c‐statistic 0.683). Variables…

Figure 4.
Factors associated with early use of aspirin in multivariable model (c‐statistic 0.683). Variables in the final multivariable model are shown along the vertical axis. The strength of effect is shown along the horizontal axis with the vertical line demarking an odds ratio (OR) of 1 (OR=1, no association); estimates to the left (OR1) indicates that patients with the characteristic have a higher likelihood of receiving aspirin than those without the characteristic. Each square and line represents the point estimate of the effect of that variable in the model, while the line shows the 95% CI. CI indicates confidence interval; NSTEMI, non‐ST‐segment elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
Figure 4.
Figure 4.
Factors associated with early use of aspirin in multivariable model (c‐statistic 0.683). Variables in the final multivariable model are shown along the vertical axis. The strength of effect is shown along the horizontal axis with the vertical line demarking an odds ratio (OR) of 1 (OR=1, no association); estimates to the left (OR1) indicates that patients with the characteristic have a higher likelihood of receiving aspirin than those without the characteristic. Each square and line represents the point estimate of the effect of that variable in the model, while the line shows the 95% CI. CI indicates confidence interval; NSTEMI, non‐ST‐segment elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.

References

    1. ISIS‐2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet. 1988; 2:349-360.
    1. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapaport E, Fuster V, Reeves TJ, Karp RB, Russell RO., Jr Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 1990; 16:249-292.
    1. Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71-86.
    1. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002; 346:1800-1806.
    1. Gao R, Patel A, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Harris P, Algert C, Groenestein P, Turnbull F. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart. 2008; 94:554-560.
    1. Liu Q, Zhao D, Liu J, Wang W. Current clinical practice patterns and outcome for acute coronary syndromes in China: results of BRIG project. Zhonghua Xin Xue Guan Bing Za Zhi. 2009; 37:213-217.
    1. Zhang LJ, Chen YD, Song XT, Zhao FH, Lu SZ. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non‐ST elevation acute coronary syndrome: insights from the Sino‐Global Registry of Acute Coronary Events. Chin Med J (Engl). 2009; 122:502-508.
    1. Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. ST‐segment elevation myocardial infarction in China from, 2001 to 2011 (the China PEACE‐Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2014
    1. The World Bank. Toward a Healthy and Harmonious Life in China: Stemming the Rising Tide of Non‐Communicable Diseases Available at: . Accessed February 8, 2014.
    1. Dharmarajan K, Li J, Li X, Lin Z, Krumholz HM, Jiang L. The China Patient‐Centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective study of acute myocardial infarction: study design. Circ Cardiovasc Qual Outcomes. 2013; 6:732-740.
    1. Cao Q, Shi L, Wang H, Dong K. Report from China: health insurance in China—evolution, current status, and challenges. Int J Health Serv. 2012; 42:177-195.
    1. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010; 56:254-263.
    1. Puymirat E, Battler A, Birkhead J, Bueno H, Clemmensen P, Cottin Y, Fox KA, Gorenek B, Hamm C, Huber K, Lettino M, Lindahl B, Muller C, Parkhomenko A, Price S, Quinn T, Schiele F, Simoons M, Tatu‐Chitoiu G, Tubaro M, Vrints C, Zahger D, Zeymer U, Danchin N. Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. Eur Heart J Acute Cardiovasc Care. 2013; 2:359-370.
    1. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation. 1995; 92:2841-2847.
    1. Becker RC, Burns M, Gore JM, Lambrew C, French W, Rogers WJ. Early and pre‐discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. J Thromb Thrombolysis. 2000; 9:207-215.
    1. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty‐year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population‐based perspective. Circulation. 2009; 119:1211-1219.
    1. National Bureau of Statistics of China. China Statistical Yearbook 2011 Available at: . Accessed February 8, 2014.
    1. Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, He J, Goldman L, Zhao D. Cost‐effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Circ Cardiovasc Qual Outcomes. 2014; 7:78-85.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner